

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
4-100-8303C/C1D1  
APPLICATION NO.  
10/092,639  
APPLICANT  
SCHULER ET AL.  
FILING DATE  
March 7, 2002

Group  
1614

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
W	AA	5,362,718	11/8/94	Skotnicki et al.	514	63	4/18/94
W	AB	5,516,781	5/14/96	Morris et al.	514	291	5/12/94
W	AC	5,665,772	9/9/97	Cottens et al.	514	514	4/7/95
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

RECEIVED  
OCT - 8 2002  
JAN 31 2003  
TECH CENTER 1600/2900

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
W	AM	WO 94/09010	4/28/94	PCT			<input type="checkbox"/>	<input type="checkbox"/>
I	AN	WO 96/41807	12/27/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>
I	AO	EP 568 310	11/3/93	Europe			<input type="checkbox"/>	<input type="checkbox"/>
I	AP	EP 551 182	7/14/93	Europe			<input type="checkbox"/>	<input type="checkbox"/>
10	AQ	EP 691 130	1/10/96	Europe			<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

W	AR	Ikonen et al., "Sirolimus (Rapamycin) Halts and Reverses Progression of Allograft Vascular Disease in Non-Human Primates", Transplantation, Vol. 70, No. 6, pp. 969-975 (2000).
W	AS	Matas et al., "Chronic Rejection", J. Am. Soc. Nephrol., Vol. 4, Suppl. 1, pp. S23-S29 (1994).
W	AT	Kahan, "The Potential Role of Rapamycin in Pediatric Transplantation as Observed from Adult Studies", Pediatr Transplantation, Vol. 3, pp. 175-180 (1999).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
4-100-8303C/C1D1  
APPLICATION NO.  
10/092,639  
APPLICANT  
SCHULER ET AL.  
FILING DATE  
March 7, 2002

Group  
1614



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Sadrani et al., "Chemical Modification of Rapamycin: The Discovery of SDZ RAD", Transplant. Proc., Vol. 30, pp. 2192-2194 (1998).
AB	Fellstrom et al., "Pathogenesis and Treatment Perspectives of Chronic Graft Rejection (CVR)", Immunological Reviews, No. 134, pp. 83-98 (1993).
AC	Meiser et al., "Effects of Cyclosporin, FK506, and Rapamycin on Graft-Vessel Disease", Lancet, Vol. 338, pp. 1297-1298 (1991).
AD	Gregory et al., "The Use of New Antiproliferative Immunosuppressants is a Novel and Highly Effective Strategy for the Prevention of Vascular Occlusive Disease", J. Heart Lung Transpl., Vol. 11, Pt. 11, p. 197 (1992).
AE	Morris et al., "Immunosuppressive Effects of the Morpholinoethyl Ester of Mycophenolic Acid (RS-61443) in Rat and Nonhuman Primate Recipients of Heart Allografts", Transplant. Proc., Vol. 23, No. 2, Suppl. 2, pp. 19-25 (1991).
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

RECEIVED  
OCT - 8 2002  
TO 1700 MAIL ROOM  
RECEIVED  
JAN 31 2003  
TECH CENTER 1600/2900

EXAMINER

*W. W. Schuler*


DATE CONSIDERED

3-6-05

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
4-100-8303C  
APPLICATION NO.  
10/092,639  
APPLICANT  
SCHULER ET AL.  
FILING DATE  
MARCH 7, 2002Group  
1714

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	CA						
	CB						
	CC						
	CD						
	CE						
	CF						
	CG						
	CH						
	CI						
	CJ						
	CK						
	CL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	CM						<input type="checkbox"/>	<input type="checkbox"/>
	CN						<input type="checkbox"/>	<input type="checkbox"/>
	CO						<input type="checkbox"/>	<input type="checkbox"/>
	CP						<input type="checkbox"/>	<input type="checkbox"/>
	CQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

lw	CR	Gregory et al., "Use of Antiproliferative Agents for the Treatment of Occlusive Vascular Disease", FASEB Journal Abstracts Part I, Anaheim, California, April 5-9, p. A940, No. 21 (1992).
f	CS	Gregory et al., "Rapamycin Inhibits Arterial Intimal Thickening Caused by Both Alloimmune and Mechanical Injury", Transplantation, Vol. 55, No. 6, pp. 1409-1418 (1993).
lw	CT	Marx et al., "Rapamycin Inhibits Phosphorylation of Retinoblastoma Protein and Blocks Vascular Smooth Muscle Cell Proliferation", Circulation, Vol. 90, No. 4, Part 2, p. I-306, No. 1646 (1994).

EXAMINER

lc - schuler

DATE CONSIDERED

3-6-05

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.